A Study of Rovalpituzumab Tesirine Administered in Combination With Nivolumab and With or Without Ipilimumab for Adults With Extensive-Stage Small Cell Lung Cancer

Stopped Enrollment was stopped after the dose-limiting toxicity (DLT) evaluation phase of Cohort 2.

Conditions

• Small Cell Lung Cancer

Interventions

• DRUG: Ipilimumab
• DRUG: Nivolumab
• DRUG: Rovalpituzumab tesirine

Sponsor

AbbVie

Collaborators

• [object Object]